The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.
Federico Rojo
No relevant relationships to disclose
Ana Lluch
No relevant relationships to disclose
Amparo Ruiz
No relevant relationships to disclose
Manuel Ruiz-Borrego
No relevant relationships to disclose
Agusti Barnadas
No relevant relationships to disclose
Lourdes Calvo
No relevant relationships to disclose
Sonia Gonzalez
No relevant relationships to disclose
Mireia Margeli
No relevant relationships to disclose
Alvaro Rodriguez-Lescure
No relevant relationships to disclose
Antonio Anton
No relevant relationships to disclose
Miguel Angel SeguĂ­
No relevant relationships to disclose
Montserrat Munoz-Mateu
No relevant relationships to disclose
Joan Dorca
No relevant relationships to disclose
Jose Manuel Lopez-Vega
No relevant relationships to disclose
Carlos Jara-Sanchez
No relevant relationships to disclose
Nuria Martin
No relevant relationships to disclose
Maribel Casas
No relevant relationships to disclose
Eva Maria Carrasco
No relevant relationships to disclose
Rosalia Caballero
No relevant relationships to disclose
Miguel Martin
No relevant relationships to disclose